Albert Oriol

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 239 publications

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Journal: Future oncology (London, England)
Published: August 30, 2026

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Journal: Future oncology (London, England)
Published: June 27, 2026

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

Journal: Future oncology (London, England)
Published: June 16, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine
Published: June 15, 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine
Published: May 29, 2026

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)
Published: April 29, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances
Published: April 03, 2026

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.

Journal: Bone marrow transplantation
Published: March 02, 2026

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood
Published: March 02, 2026

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: February 25, 2026

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Journal: HemaSphere
Published: December 23, 2025

Study of post-translational modifications of p53 in multiple myeloma.

Study of post-translational modifications of p53 in multiple myeloma.

Journal: Blood cancer journal
Published: December 10, 2025
Showing 1-12 of 239

Last Updated: 09/26/2026